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ABSTRACT
Genome editing with the CRISPR–Cas9 system has
enabled unprecedented efficacy for reverse genetics
and gene correction approaches. While off-target ef-
fects have been successfully tackled, the effort to
eliminate variability in sgRNA efficacies––which af-
fect experimental sensitivity––is in its infancy. To ad-
dress this issue, studies have analyzed the molec-
ular features of highly active sgRNAs, but indepen-
dent cross-validation is lacking. Utilizing fluorescent
reporter knock-out assays with verification at se-
lected endogenous loci, we experimentally quanti-
fied the target efficacies of 430 sgRNAs. Based on
this dataset we tested the predictive value of five
recently-established prediction algorithms. Our anal-
ysis revealed a moderate correlation (r = 0.04 to r =
0.20) between the predicted and measured activity of
the sgRNAs, and modest concordance between the
different algorithms. We uncovered a strong PAM-
distal GC-content-dependent activity, which enabled
the exclusion of inactive sgRNAs. By deriving nine
additional predictive features we generated a linear
model-based discrete system for the efficient selec-
tion (r = 0.4) of effective sgRNAs (CRISPRater). We
proved our algorithms’ efficacy on small and large
external datasets, and provide a versatile combined
on- and off-target sgRNA scanning platform. Alto-
gether, our study highlights current issues and ef-
forts in sgRNA efficacy prediction, and provides an
easily-applicable discrete system for selecting effi-
cient sgRNAs.
INTRODUCTION
Genome editing promises the ability to probe genetic in-
teractions at their origin and the opportunity to cure
severe inherited diseases. With the development of the
clustered regularly interspaced short palindromic repeats
(CRISPR)––CRISPR-associated-9 (Cas9) technology, new
avenues for versatile genome editing have opened due to
the minimal selection criteria of its target site––the pro-
tospacer adjacent motif (PAM)––and its high overall ac-
tivity (1–3). After initial doubts about off-target activity-
induced safety issues (4–6), recent advances in understand-
ing sgRNA/Cas9 function –based on crystal structures of
Cas9-DNA-RNA interaction (7,8)––guided protein engi-
neering of the S. pyogenes Cas9 towards an expanded PAM
repertoire (9) and increased safety (10). This, as well as the
availability of Cas9 proteins from other bacterial strains
(11–13), and a plethora of approaches to decrease off-target
activity (14–16), have since eliminated nearly all restrictions
of target site selection. However, variance in genome editing
efficacy remains a limitation for translational approaches
and lowers the signal-to-noise ratio of large-scale genetic
screens. While this constraint may have its basis in Cas9
functions, like efficient DNA-scanning (17) and PAM de-
tection (7,8), or nuclease domain activation (8,18), a distinct
requirement for nucleotide composition of the sgRNAmay
cause reasonable variances in genome editing efficacy.
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When short hairpin RNAs (shRNAs) were first devel-
oped they similarly showed highly variable knock-down re-
sults, which were overcome by tiling experiments that de-
termined sequence requirements for highly active shRNAs
(19,20). In line with this approach, several recent studies
have aimed to decipher themolecular nature of active versus
inactive sgRNAs (21–29). Wang et al. detected an increased
loading of efficient sgRNAs onto the Cas9 protein by Cas9-
RIP, and derived sequence properties for these sgRNAs
(21). This theme was further addressed by Moreno-Mateos
et al., and connected to guanine-dependent sgRNA stability
(26). Tiling approaches similar to the successful screenings
for efficient shRNAs (19) have focusedmore on the genomic
target site of the sgRNA/Cas9 complex, including the in-
fluence of the precise PAM sequence and both upstream
and downstream sequences (22,24,26,29). In addition, Xu
et al. performed RNA-seq and incorporated sgRNA fold-
ing energies into the mix (27), while Malina et al. discov-
ered that PAM sequences within the sgRNA inhibit its ac-
tivity (25). The idea that sgRNA foldingmay be a confound-
ing factor for sgRNA-dependent genome editing activity
was further addressed by Chu et al., who evaluated spacer
sequence-determined sgRNA folding as a potential modi-
fier of genome editing activity which may cause improper
recognition by Cas9 and thus reduced genome editing (30).
These studies have all generated predictive algorithms and
provided scoring systems to identify highly active sgR-
NAs compared to less active ones. However, an indepen-
dent validation and comparison between these prediction
algorithms using an experimentally-established, quantita-
tive dataset of sgRNAs was lacking until now.
We present findings from a dataset of 430 lentivirally-
delivered sgRNAs, tested via surrogate fluorescent reporter
knock-out assays that allow the assessment of sgRNAs at
the genomic level with single-cell resolution. Meta-analysis
of existing algorithms and features for sgRNA prediction
suggested only a moderate capacity to recapitulate the
observed activities of lentivirally-delivered sgRNAs from
our dataset. This was further underlined by modest con-
cordance between prediction algorithms. By probing our
dataset for potential predictive features, we developed an
experimentally-defined discrete model for the prediction of
sgRNA efficacy, which enables the exclusion of low-efficacy
candidates and is publicly available as an additional tool
within the CCTop online platform (http://crispr.cos.uni-
heidelberg.de/). Our study thereby highlights current ob-
stacles in the prediction of sgRNA activity, outlines poten-
tial ways to overcome these hurdles, and provides efficient
methodologies to select highly active sgRNAs for focused
approaches.
MATERIALS AND METHODS
Vectors and sgRNA design
The lentiviral CRISPR–Cas9 plasmids, and the tRFP657-
and dTomato-labeled CRISPR–Cas9 efficacy reporter plas-
mids have been described before (31,32). The sgRNA ex-
pression vector SGL40C.EFS.E2Crimson (#100894) and
the SIN40C.SFFV.sfGFP-Rep.iPAC (#100893) CRISPR–
Cas9 efficacy reporter plasmids have been deposited at Ad-
dgene.
CRISPR–Cas9 target sites and sgRNAs were selected
and designed using the CCTop online target prediction tool
with maximal avoidance of off-target effects (33).
Viral particle production
Lentiviral particles were generated by transient transfection
of 293T cells using polyethylenimine (PEI, Polysciences).
Lentiviral vectors (described above) were co-transfected
with the psPAX2 packaging plasmid (Addgene, Plasmid
#12260) and the pMD2.G envelope plasmid (Addgene,
Plasmid #12259). Particles were either used directly by ap-
plying the supernatant of transfected 293T cells, or they
were concentrated by ultracentrifugation.
Cell culture and cell transduction
293T cells (German National Resource Center for Biologi-
calMaterial (DSMZ)) were cultured inDMEM (Biochrom)
supplemented with 10% FCS, 1% penicillin/streptomycin,
1% sodium pyruvate, 1% L-glutamine, and 1% non-
essential amino acids (all Life Technologies). HEL cells
(DSMZ) were cultured in equally supplemented RPMI
1640 (Lonza). HEL cells were transduced in the presence
of 5 g/ml hexadimethrine bromide (Polybrene, Life Tech-
nologies).
Fluorescent reporter assay
HEL cells were transduced with the CRISPR–Cas9 re-
porter vector containing the respective target sites in-frame
with a sfGFP cDNA. Fluorescence was checked 48 h after
transduction by flow cytometry and cultures with 15–25%
transduction rate were subjected to selection with 2 g/ml
puromycin (Life Technologies) for 72 h. The selection step
was verified by flow cytometry.
Subsequently, cells expressing the reporter construct were
super-transduced with lentiviral vectors encoding SpCas9,
the sgRNA and a fluorescent protein. Six days after super-
transduction, cells were analyzed by flow cytometry (BD
FACSCanto™ [BDBiosciences]). Cleavage efficacies of sgR-
NAs were calculated by the loss of reporter fluorescence
compared to a non-targeting sgRNA.
T7-endonuclease I assay
HEL cells were transduced with CRISPR–Cas9 vectors
containing the respective sgRNA, the SpCas9 cDNA, a
puromycin resistance cassette and the eGFP cDNA. Start-
ing at 48h post-transduction, cells were selected with 2
g/ml puromycin (Life Technologies) for 72–96 h, followed
by flow cytometric verification. Genomic DNA was iso-
lated using the DNA Mini Kit (Qiagen) according to the
manufacturer’s instructions. PCR amplicons asymmetri-
cally spanning the genomic target site of the individual sgR-
NAs (Supplementary Table S2) were produced using stan-
dard protocols with the Extensor 2x Master Mix (Thermo
Scientific). Fragments were purified (Gel Extraction Kit
[Thermo Scientific]), then melted and re-annealed by heat-
ing to 96◦C for 5min and slowly cooling down to room tem-
perature. 350 ng of PCR products were incubated with 10
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U T7-endonuclease I (NEB) in a total volume of 20 l at
37◦C for 22 min, and loaded onto a 1.5% agarose gel for
analysis. For absolute quantification of cleaved products,
the signal intensities of DNA bands were determined and
converted by reference to defined amounts of DNA ladder
input (Thermo Scientific) using the GelDoc XR system and
ImageLab 3.0 software (both BioRad).
Statistical analyses
Statistical analyses were performed using GraphPad
Prism® version 6.07. Significance levels of normally and
non-normally distributed data were calculated using the
Student’s t-test and the Mann–Whitney test, respectively.
All boxplot graphs show the median and interquartile
ranges, unless otherwise stated. Significance levels of linear
correlations were calculated using a two-tailed f-test.
Prediction model creation
Feature extraction and modeling of sgRNA efficacy was
performed as previously described (34). In brief, adopting
a similar approach as Vert et al. (35), the efficacy predic-
tion model was built by applying the R package lars (36) to
the knock-out efficacies of 426 sgRNAs assessed by the sur-
rogate fluorescent reporter assay (flow cytometry-based).
The predictive capacity of each positional sequence feature
was assessed via linear modelling and calculation of the re-
spective root-mean-square-error (RMSE) as the mean over
all sgRNAs. After subsequent ranking on RMSE, the 10
best features available for all sgRNAs were selected. To ob-
tain a feature combination capable of rating sgRNA effica-
cies (CRISPRater), the mean RMSE for all possible feature
combinationswas calculated and the bestmodel with lowest
RMSEwas selected. Validation of themodel was performed
on the 426 sgRNAs, one internal dataset, and three pub-
lished external datasets: (i) an independent set of 45 sgR-
NAs not used to train the algorithm (Supplementary Table
S1), (ii) a dataset by (21,27,37) consisting of 3141 sgRNAs
assessed by their effects on proliferation (27), (iii) 20 sgR-
NAs assessed by cleavage efficacy (27) and (iv) 15 sgRNAs
assessed by protein level expression (27) (all Supplementary
Table S3).
RESULTS
Surrogate fluorescent reporter knock out assays are predic-
tive for targeted DNA cleavage at genomic loci
Aiming to establish highly efficient sgRNAs for genome
editing applications, we developed a lentiviral-based re-
porter system that allows quantitative testing of the genome
editing efficacies of 20–40 sgRNAs simultaneously at the
genomic level (31) (Figure 1A). The vector was optimized
to provide a robust fluorescence signal despite insertion of
random amino acids into the fluorescent protein. This was
tested by inserting the same sgRNA target sequence into
different fluorescent proteins (n = 5, 126–276 amino acids
in length). Among the tested fluorescent proteins, the fast-
folding version of eGFP (sfGFP) (38) showed the highest
and most stable fluorescence (Supplementary Figure S1A-
B). Coupled to flow cytometry, this reporter system allows
us to assess genome editing efficacy at the single-cell level,
and to distinguish highly active sgRNAs from less active or
inactive ones in a highly consistent manner (Figure 1B-C;
Supplementary Figure S1C). Incorporation of the highly ef-
ficient target site of murine Tet2 yielded an average cleav-
age rate of 89.44% (n = 16, SD: ±2.64%), thus assuring
the reproducibility and cross-experiment comparability of
these assays. This result is in line with recent findings that
CRISPR–Cas9 efficacy is independent from target site copy
number variations (39).
Chromatin accessibility has been reported to alter
CRISPR–Cas9 efficacies (40). In utilizing a non-randomly
integrating lentiviral reporter system that preferentially in-
tegrates in open chromatin (41), the native chromatin struc-
ture of the target site is eliminated, which may limit the pre-
dictive value of our assay. To address this potential issue,
we selected a total of 17 sgRNAs with different activities in
our reporter assay: six sgRNAs with low activity (∼0–25%
cleavage efficacy), four sgRNAs with intermediate activity
(∼50–65%), and seven sgRNAs with high activity (∼80–
95%). T7-EI assays were performed to test DNA modifi-
cation at the designated genomic loci (Figure 1D-E). These
results verified a high correlation (r= 0.84) between sgRNA
activity in the reporter assay and at the genomic locus. Thus,
high predictivity for genome editing activity at the endoge-
nous genomic site was retained despite the use of a non-
randomly integrating reporter system.
Lentivirally-deliveredCRISPR–Cas9 has an inherent high ef-
ficacy
Having experimentally established a biologically neutral
readout-based reporter system capable of single-cell reso-
lution, we generated a dataset of 430 sgRNAs (Supplemen-
tary Table S1) and first analyzed their individual cutting ef-
ficacies (Figure 2A). Of note, sgRNA design was restricted
to the avoidance of off-target sites as the only selection crite-
rion for spacers/protospacers (5,33). Following these guide-
lines, we have shown before that high-scoring sgRNAs in
our reporter assays have no detectable off-target activity
(31,32). Without any further consideration for target se-
quence features or genomic context, our dataset had a me-
dian cleavage activity of 76.1% (mean: 67.2%; range: 0% to
99.7%). The likelihood of retrieving highly efficient (efficacy
>80%) or inefficient sgRNAs (efficacy<40%) after random
selection of target sites was 40.7% and 16.3%, respectively.
Based on these observations, evaluating three sgRNAs per
target gene should be sufficient to yield a highly efficient
one.
Established prediction algorithms for sgRNA efficacy have
limited value
Next, we investigated whether the cleavage efficiencies of
sgRNAs in our dataset could be correctly predicted by exist-
ing algorithms, all of whichwere establishedwith large-scale
library approaches (22,26,27,29). To this end, we retrieved
efficiency scorings for our tested sgRNAs using sgRNA
Designer, the first openly available platform generated by
Doench et al. (22). By targeting twelve cell surface recep-
tors on murine and human cell lines with a total of 1,841
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Figure 1. Evaluation ofCRISPR–Cas9 cleavage utilizing a fluorescent based reporter-assay. (A) Schematic presentation of the reporter construct. CRISPR–
Cas9 target sites are integrated into the ORF of a sfGFP (super-folder GFP) cDNA. Puromycin resistance enables selection of HEL cells harboring the
reporter construct. Genome editing generates frame-shift mutations leading to quantifiable loss of fluorescence. (B, C) Representative flow cytometry anal-
yses of a reporter assay. X-axis: sfGFP reporter fluorescence; Y-axis: fluorescence of the provided CRISPR–Cas9 components, namely, a non-targeting
sgRNA (B) and a targeting sgRNA (C). (D) An example of T7-endonuclease I assay results, and correlation of genomic modification efficacies at endoge-
nous loci with results from the reporter assay. [M] DNAmarker; [+] targeting sgRNA; [–] non-targeting sgRNA. (E) Correlation of reporter assay efficacies
(x-axis) and T7-endonuclease I assay efficacies (y-axis). Pearson correlation (r) and P value (p) are indicated.
sgRNAs, Doench et al. found that only∼5% of all sgRNAs
are highly effective. In line with this result, their algorithm
(rule set I) predicted the majority of sgRNAs in our dataset
to have low cleavage efficiency (score <0.25: 62.1%). This
resulted in a poor but statistically significant correlation be-
tween the prediction score of sgRNADesigner and our mea-
sured cleavage efficiency (r = 0.118; p = 0.015; 1.04-fold
activity at rule set I score >0.7 versus <0.2 (Figure 2B)).
With a more advanced algorithm by Doench et al. (rule
set II) (29), the predictive value increased and higher activ-
ity scores were obtained in our dataset (Figure 2C). Cross-
comparison between the two algorithms (rule set I and II)
illustrated the different predicted activities they assigned to
our sgRNAs (Supplementary Figure S2A).
We next tested the alternative library-on-library ap-
proach, sgRNA Scorer by Chari et al. (24), on our dataset.
The correlation between our data and the predicted activi-
ties from this algorithm did not improve compared to rule
set II (29), although a trend of high scores matching to
higher measured efficacy was still visible (Figure 2D). To
further compare the predictive capacity of these algorithms,
we performed a cross-comparison of rule set I (Supplemen-
tary Figure S2B) and rule set II (Supplementary Figure
S2C) with Chari et al.’s approach, yielding positive correla-
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Figure 2. Experimentally-ascertained cutting efficacies of 430 sgRNAs can be partially predicted by five up-to-date online prediction tools. (A) Distribution
of the individually-assessed cleavage efficacies of 430 sgRNAs targeting a total of 92 genes (54 human and 38 murine), calculated on the basis of reporter
assay analyses. The dataset shows median cleavage efficacy of 76.1% (interquartile range: 52.9 to 85.8%). (B–F) Scatter plots showing the correlation
between sgRNA-specific cleavage efficacies obtained from reporter assays (y-axes) and predicted scores obtained from sgRNA sequence analysis using the
online tools sgRNA Designer (rule set I) (22) (B), sgRNA Designer (rule set II) (29) (C), sgRNA Scorer (24) (D), SSC score (27) (E) and CRISPRscan (26)
(F) (x-axes). The Pearson correlations (r) and P values (p) are indicated.
tion of the incorporated features but with reasonable vari-
ability.
Contrasting these approaches, efforts have also been ded-
icated towards distinguishing efficient from non-efficient
sgRNAs. Xu et al. utilized published CRISPR–Cas9 drop-
out screening data (21,37) to derive 28 characteristics from
sgRNAs showing twofold higher sgRNA efficacy than their
less active counterparts for the same genes (SSC score).
Analysis of our sgRNAs based on these characteristics
resulted in a moderate correlation between the provided
scores andmeasured efficacies, while cross-comparisonwith
formerly tested algorithms also showed intermediate-level
correlation (Figure 2E; Supplementary Figure S2D-F).
We further proceeded to compare our data to the sgRNA
prediction algorithm produced by Moreno-Mateos et al.,
CRISPRscan, which is based on in vivo knock-out data
from zebrafish, and which indicated strong G-richness and
higher stability within efficient sgRNAs (26). Hampered
by the algorithm’s immediate exclusion of sgRNAs labeled
to be inefficient, we only retrieved scorings for 11.2% of
our sgRNAs. Since this result may indicate inferior perfor-
mance of the excluded sgRNAs, we compared efficiencies
but did not observe any significant differences between the
included and excluded sgRNAs (76.1% versus 75.7%, p =
0.4380, Supplementary Figure S2G). In line with this result,
the characteristics derived by Moreno-Mateos et al. had no
predictive capacity in our dataset and poor or no correla-
tion with other tested algorithms (Figure 2F; Supplemen-
tary Figure S2H-K).
In conclusion, we retrospectively tested five sgRNA
prediction algorithms on our experimentally-established
dataset of 430 CRISPR–Cas9 targets. We observed mod-
erate predictive capacity (r = 0.17 to r = 0.2) for three
(24,27,29) out of five algorithms and moderate cross-
comparability of the tested tools, indicating their benefit for
large-scale library generation but modest performance for
individual sgRNA/target design.
Purine bases at PAM-proximal sgRNA position 20 enhance
genome editing efficacy
Next, we thought to interrogate our dataset for existing and
novel features that may help in the design of efficient sgR-
NAs. Previously-identified features involving a nucleotide-
dependent influence on CRISPR–Cas9 cutting efficacy are
the nucleotide at the PAM-proximal position 20 (22) and
the variable nucleotide of the PAM (22,42). Analysis of the
variable nucleotide of the S.pyogenes PAM showed no im-
pact on sgRNA activity in our dataset (Supplementary Fig-
ure S3A-D).
In contrast, sgRNA position 20 exhibited a guanine
(G20)-dependent increase of genome editing activity in our
dataset, as has been previously shown (21). Additional as-
sessment of all four nucleotide options emphasized the im-
pact of G20 on sgRNA activity, with a 9.2% and 8.8% in-
crease compared to thymine and cytosine at position 20,
respectively. However, no significant increase was observed
between G20 versus an adenine at this position (Figure 3A).
Thus, both purine bases (G and A) appear to have a fa-
vorable impact on Cas9 performance compared to pyrim-
idine bases (C and T) (Supplementary Figure S3E–G). In-
clusion of A20 into the criteria for sgRNA selection could
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Figure 3. Investigation of sgRNA sequence features capable of increasing genome editing capacity. (A) Efficacies of sgRNAs subdivided based on nucleotide
usage at position 20 (adjacent to the PAM). Efficacy increased by 9.2% and 8.8% for G versus T and G versus C, respectively, and both are statistically
significant by the Mann–Whitney test. (B) Comparison of sgRNA efficacy based on genomic origin of the target site. The sgRNAs target intronic regions
(median 69.0%, interquartile range: 40.5–80.6%, n = 154), exonic regions (median 78.7%, interquartile range: 55.1–87.1%, n = 222) and promoter regions
(median 80.7%, interquartile range: 74.8–87.2%, n = 54). Mann-Whitney test results are as indicated. (C–F) Depiction of GC-content dependent sgRNA
activity. Overall GC: no significant differences (C). 1.78-fold to 1.87-fold reduction of efficacy in sgRNAs with <25% GC within nt 1–10 (n = 14) (D).
GC-content has no effect on activity within nt 11–20 (E). Narrowed-down GC window size (5 nt) of PAM-distal GC-content: 1.36–1.41-fold reduction of
efficacy with <25% GC within nt 4–8 (n = 50) (F). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001; Mann–Whitney test used in all cases.
thus increase the likelihood of retrieving efficient sgRNAs
compared to selection based on G20 only.
Genomic origin of target sites influences sgRNA efficacy in a
chromatin-independent manner
Since our dataset contained not only sgRNAs targeting
coding regions, but also included targets in non-coding
genome elements, we next asked if the genomic origin of the
target sites may help identify molecular features that guide
the activity of the CRISPR–Cas9 system. We therefore first
subdivided our dataset into sgRNAs targeting sites derived
from coding (n = 222) or non-coding (n = 208) regions of
the genome (Supplementary Figure S4A-B). Indeed, sgR-
NAs targeting non-coding regions of the genome performed
significantly worse compared to coding regions (median:
73.6% versus 78.7%; p = 0.0082) (Supplementary Figure
S4C). The non-coding part of the genome is versatile in its
function and nucleotide composition, and this initial obser-
vation led us to interrogate sgRNA efficacies at non-coding
loci in more detail. Since we targeted promoter regions (de-
fined as TSS –200 to +50) and intronic regions, we again
subdivided the non-coding sgRNAs into these categories
and compared them to sgRNAs targeting exonic regions
(Supplementary Figure S4D-E). Interestingly, sgRNAs tar-
geting promoter regions yielded the highest median efficacy
(80.7%, n = 54), while sgRNAs targeting intronic regions
performed worst overall (69.0%, n = 154). Those sgRNAs
targeting exonic regions showed an intermediate level of ef-
ficacy (78.7%, n = 222) (Figure 3B). Of note, since these
results were obtained by lentiviral reporter assays, all proto-
spacers were non-randomly integrated into the genome (41)
at different loci without their native neighboring sequence
or native epigenetic state. Due to the absence of these poten-
tial modifiers of genome editing activity in the lentiviral re-
porter assay, it ismore likely that the detected differences be-
tween sgRNAs derived from different genomic regions are
caused by particular sequence features.
GC-content discriminates low efficacy sgRNAs but is no iden-
tifier for maximum efficacy
The significant differences in sgRNA activity at sequences
derived from different regions of the genome prompted us
to investigate themolecular features of the sgRNAs in terms
of nucleotide composition. First, the overall GC-content of
the sgRNA spacers were tested, as GC-content differs be-
tween non-coding and coding genome regions (43,44) and
as it was previously shown to influence sgRNA activity
(21,22). Only a minor and non-significant increase in per-
formance was found for sgRNAs with a GC-content of 41–
55% (p= 0.3713) or 56–70% (p= 0.1346), compared to sgR-
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NAs with <40% or >70% GC-content (Figure 3C). Our
dataset thus does not reproduce former findings that in-
dicate an optimal intermediate GC-content, with decreas-
ing sgRNA performance towards low and high GC-content
(22,23).
Nevertheless, we saw variations in sgRNA efficacy with
changes in GC-content and we hypothesized that only some
regions of the sgRNA are affected by this feature, as has
been previously observed (23). To this end we split the
sgRNA sequence into sub-intervals. Due to the contro-
versy regarding a functional seed region for logical splitting
(1,40,45,46), we split the sgRNA sequence into 50% inter-
vals starting with a PAM-proximal and a PAM-distal half
and analyzed their GC-content independently (Figure 3D-
E). Indeed, medium and highGC-content within the first 10
nt of the sgRNA (distal to the PAM) significantly increased
genome editing activity. In comparison to a GC-content of
<25%, a GC-content of 26–50% increased sgRNA efficacy
by 1.80-fold (p = 0.0077). The same result was seen when
comparing<25% to even higher GC-content (GC 51–75%:
1.78-fold; p = 0.0088 and 76–100%: 1.87-fold; p = 0.0281).
Notably, GC-content in the PAM-proximal half showed no
significant impact on sgRNA efficacy.
Having verified our hypothesis that sub-regions of the
sgRNA are sensitive towards varying GC-content, we next
performed complete tilingwith a 10 nt window size (Supple-
mentary Figure S5A), and found a positive impact of high
GC up to position 13 (Supplementary Figure S6). How-
ever, the strongest resolution of sgRNA efficacy could be
obtained by analysis of nucleotides 1–10 (GC >25% ver-
sus <25%: 1.78-fold to 1.87-fold efficacy), thereby mark-
ing 3.3% of all sgRNAs as very ineffective. Of note, our
analyses were performed on native sequences before the
addition/substitution of a guanine at position one for U6
promoter initiation. Tiling for GC-content-dependent ef-
ficacy with a 5 nt window (Supplementary Figure S5B)
yielded similar results for the PAM-distal half of the
sgRNA (Supplementary Figure S7). The highest resolution
of sgRNA activity was obtained in the window from po-
sition 4–8 (GC >25% versus <25%: 1.36-fold to 1.41-fold
efficacy, Figure 3F). Application of this narrowed window
size elevated the proportion of excludable low-efficacy sgR-
NAs to 11.2%.
Given the initial observation that genome editing efficacy
varied based on which genomic origin (exon, intron, pro-
moter) the sgRNA target sites were derived from, and con-
sidering known differences in GC-content in the genome
(43,44), we wondered if the likelihood of retrieving sgR-
NAs with low GC1–10 or GC4–8 differs based on genomic
origin. While the average GC1–10 and GC4–8 was within the
optimal range for all genomic origins, we could observe
a gradual and significant increase of GC1–10 and GC4–8
from intron- to exon- to promoter-derived sgRNAs, and a
concomitantly decreased likelihood of retrieving sgRNAs
with critically low (<25%) GC1–10 and GC4–8 (Supplemen-
tary Figure S8). In detail, the likelihood of retrieving a
sgRNA with critically low GC1–10 was 6.5%, 2.3%, and 0%
for intron-, exon- and promoter-derived sgRNAs, respec-
tively. The likelihood of retrieving a sgRNA with critically
low GC4–8 was 17.5%, 9.3%, and 1.9% for intron-, exon-,
and promoter-derived sgRNAs, respectively. Thus, intron-
derived sgRNAs are more likely to have a critically low
GC1–10 and GC4–8, which may be caused by known differ-
ences in GC content within the genome (43,44).
Next, we sought to perform a biased search for genome
editing activity-determining sequence features within de-
fined sgRNA efficacy windows (Figure 4A). A similar
approach has recently been successfully used to refine
shRNA prediction (34). We tested different sgRNA effi-
cacy windows to achieve the best separation of poorly-
and well-performing sgRNAs, resulting in grouped sgRNA
fractions with activities of <40% (sgRNAL) and >70%
(sgRNAH) (Figure 4A), respectively. Comparison between
the sgRNAH and sgRNAL groups again displayed amarked
difference in GC-content spanning the PAM-distal nu-
cleotides 4–13 (GC4–13) (Figure 4B).
In summary, our analyses strongly suggest that monitor-
ing the GC-content in the PAM-distal 4–13 nt allows for
the exclusion of the most inefficient sgRNAs. Together with
an expanded repertoire for position 20 of the sgRNA (G/A
versus G only), these features could be leveraged to enhance
sgRNA library construction in the future.
Sequence logo examination outlines a PAM-distal GC-
content led prediction model
To obtain a more complete picture of the features that
shape genome editing efficacy, and to utilize them for rat-
ing prospective sgRNAs, we performed an expanded fea-
ture analysis that further tested single-base features includ-
ing single nucleotide exclusion, and dual-base features. The
predictive value of each potential feature was assessed by
calculating a linear model and the respective root-mean-
square-error (RMSE) as the mean over all sgRNAs, as
has been performed before for shRNAs (34). After rank-
ing on RMSE, we derived a set of ten potent predictors of
sgRNA efficacy (Figure 4C): five features positively affect-
ing sgRNA activity (GC4–13, weight = 0.14; G20, weight =
0.07; TA3, weight = 0.04; GA12, weight = 0.03; G6, weight
= 0.02) and five features negatively affecting sgRNA effi-
cacy (TA4, weight = –0.05; GA18, weight = –0.05; CA5,
weight = –0.07; G14, weight = –0.07; A15, weight = –0.08).
Notably, GC4–13 had a larger positive impact on sgRNA ef-
ficacy than the commonly-detected G20 (Figure 4C).
To obtain a model capable of rating sgRNAs based on ef-
ficacy (CRISPRater), the mean RMSE for all possible fea-
ture combinations was calculated and the best model with
the lowest RMSE was selected. The overall difficulties with
presenting sgRNA efficacy as a continuous model that we
observed in our study prompted us to generate a discrete ex-
clusion approach for the separation of low (<0.56), medium
(0.56–0.74) and high (>0.74) efficacy sgRNAs (Figure 4D).
CRISPRater proved to be superior at predicting sgRNA ef-
ficacy compared to the single feature of PAM-distal GC.
Moreover, CRISPRater selected substantiallymore efficient
sgRNAs than random selection (low versus medium: 1.55-
fold; low versus high: 1.71-fold), while maintaining high
dataset coverage (low-efficacy group: 12.2% of total). This
we validated on an independently-tested set of 65 sgRNAs
(Figure 4E). Notably, the prediction accuracy obtained by
CRISPRater exceeds what we were able to achieve with es-
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Figure 4. CRISPRater: a 10-feature-based algorithm capable of predicting sgRNA activity via a discrete model. (A) Distribution of sgRNA efficacies
within the reporter assay dataset. sgRNAs defined as low-efficiency (<40% efficacy, n = 70) and high-efficiency (>70%, n = 265) were segregated. (B)
Average GC-content compared between high-efficiency and low-efficiency sgRNAs. The high-efficiency group displayed a higher overall GC-content from
nt 4 to nt 13. (C) Most potent sequence features modulating sgRNA efficacy (five positively- and five negatively-modulating) extracted from 1024 features
by individual feature weight. (D) Boxplot showing separation of the sgRNA dataset into low-efficiency (score <0.56, n = 52), medium-efficiency (score
0.56–0.74, n= 274) and high-efficiency (score>0.74, n= 100) groups according to discrete CRISPRater modeling, thereby excluding 12.2% of sgRNAs as
low-efficiency (****P ≤ 0.0001 by use of Mann–Whitney test). (E) Validation of CRISPRater on 65 subsequently-designed sgRNAs not used to train the
algorithm. The scatter plot shows a positive correlation between CRISPRater scores and measured sgRNA efficacies. Pearson correlation (r) and P value
(p) are indicated.
tablished algorithms by 1.5–1.6-fold (Supplementary Fig-
ure S9; Figure 2B–F).
CRISPRater efficiently predicts sgRNA activity in small-
and large-scale sgRNA datasets
For in-depth analysis of CRISPRater, we first selected in-
dependent large-scale datasets from various experimental
sources generated byWang et al. (21) and Koike-Yusa et al.
(37), as derived by Xu et al. (27). Using the CRISPRater
algorithm to predict efficient sgRNAs in a discrete man-
ner yielded a highly significant selection of efficiently-acting
sgRNAs––improving library design by 1.27-fold while re-
taining 91.2% of the libraries’ sgRNAs (combined medium
and high efficiency groups), or by 1.19-fold while retain-
ing 24.0% of the sgRNAs (high efficiency group only) (Fig-
ure 5A). Given that established sgRNA prediction algo-
rithms are mainly limited to improving large-scale libraries,
we aimed to test CRISPRater on independently established
small datasets.We therefore retrieved the genome editing ef-
ficacy data of 20 sgRNAs tested for DNA modification via
T7-EI (27), and of 15 sgRNAs tested for protein reduction
(27), and we were able to show significant predictive value
in both cases (Figure 5B-C).
In summary, our studies resulted in a feature-based dis-
crete model of sgRNA efficacy, providing an efficient and
verified tool for future studies and enabling sgRNA selec-
tion processes for small and large-scale projects. Combined
with established, powerful off-target prediction (33) our
novel selection system is publicly available (http://crispr.cos.
uni-heidelberg.de/) to help improving future genome edit-
ing efforts.
DISCUSSION
Despite increased application of the CRISPR–Cas9 system
in basic research and translational approaches, guidelines
for efficacy-orientated design of sgRNAs are still contro-
versial. To investigate this issue, we utilized an optimized
reporter system and individually analyzed the genome edit-
ing efficacies of 430 sgRNAs derived from various genomic
origins. Based on this dataset we evaluated the performance
of established sgRNA efficacy prediction algorithms, out-
lined novel molecular aspects that enable the discrete rating
of sgRNAs efficacies, and provide an advanced online tool
that predicts both on- and off-target sgRNA efficacies.
The biologically neutral readout of our reporter assay, its
high concordance with the actual genomic cleavage efficacy,
its reproducibility and its throughput demonstrate that it is
a practical and verified method for focused evaluation of
sgRNA efficacy. Meanwhile, the inherently high efficacy of
the CRISPR–Cas9 system resulted in a low degree of sep-
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/46/3/1375/4754467 by U
niversidad de O
viedo. Sección de Adquisiciones user on 18 D
ecem
ber 2018
Nucleic Acids Research, 2018, Vol. 46, No. 3 1383
Figure 5. Predictivity validation of the CRISPRater score based on external experimentally-assessed cutting efficacies. (A) Validation of CRISPRater on a
combined sgRNA dataset (n = 3141 sgRNAs) derived by Xu et al., proving its predictive capacity (****P ≤ 0.0001 by use of Mann–Whitney test). (B and
C) Scatter plots showing correlations of CRISPRater predicted cutting efficacies (x-axes) and experimentally-tested efficacies from Xu et al. (27) (y-axes).
Positive correlations can be seen with n= 20 efficacies tested on the genomic level via the Surveyor assay (B), and with n= 15 efficacies tested on the protein
expression level (C). Pearson correlations (r) and P values (p) are indicated.
aration of measured sgRNA activities, illustrating a major
hurdle on the road towards accurate prediction of genome
editing efficacy. In line with this challenge, retrospective
analysis of established efficacy guidelines (22,24,26,27,29)
on our experimentally-tested sgRNAs revealed that these
prediction algorithms achieved only moderate benefit and
reliability in the design of individual sgRNAs, despite hav-
ing a significant impact on large-scale datasets. The diffi-
culties of predicting sgRNA-mediated genome editing effi-
cacy were further highlighted in cross-comparisons between
the different algorithms, which again showed onlymoderate
concordance. These results indicate a high degree of vari-
ability in the sgRNA features that were detected and incor-
porated into the different prediction models.
Aside from the high overall activity of the CRISPR–Cas9
system hampering a good separation of low and high activ-
ity sgRNAs, low cutting efficacies (24) or failure to avoid
off-target effects (22) may have introduced biases in the
datasets utilized to establish prediction rules, thus prevent-
ing unimpaired transfer of the underlying features to other
datasets. These potentially confounding factors differ be-
tween the studies, and may have been amplified by the use
of dissimilar Cas9/sgRNA delivery methods, possibly re-
sulting in differences in genome editing kinetics or efficacy.
In line with this, the use of different sgRNA backbones (47)
may impact the ability to utilize features like sgRNA fold-
ing (30) for efficacy prediction, which we could not verify in
our study (Supplementary Figure S10). Furthermore, the
use of biological readouts like cell depletion (21,26) or drug
resistance (29)––which can greatly vary between the cho-
sen targets––may have added to the difficulties preventing
more precise predictions of sgRNA efficacy. Notably, al-
though genomic accessibility has been controversially dis-
cussed with regard to its impact on genome editing activ-
ity (24,26), it is unlikely to explain any variation in our
study, given our use of the non-randomly integrating lentivi-
ral reporter assay and its high correlation with cleavage at
the respective endogenous locus. Further contrasting for-
mer studies, our data is characterized by high cleavage ef-
ficacy, prior scanning for off-target activity, and a biologi-
cally neutral readout on top of constitutive genomic acces-
sibility, and may thus serve as a solid basis to establish more
reliable prediction guidelines.
Since not only epigenetic state but also nucleotide content
differs between functionally diverse regions of the genome
(43,44), we additionally separated our sgRNA dataset by
genomic origin of the target sites. Indeed, we could show
that genomic origin is a major confounding factor for
sgRNA activity in our dataset (efficacy: promoter > ex-
onic> intronic). Upon interrogating sequence features that
may explain these differences, we discovered that the PAM-
distal––but not overall––GC-content of the sgRNA cor-
relates with its efficacy, which we could track to an in-
creased likelihood of retrieving sgRNAs with critically low
PAM-distal GC content (<25%) when scanning intronic
DNA regions. Monitoring of PAM-distal GC-content thus
represents an easily-applicable method for excluding sgR-
NAs with the lowest activity level (11.3%, 1.36-fold activ-
ity; 3.3%, 1.8-fold activity), which may have been missed
by studies testing for overall GC-content (21,22). In con-
trast, high overall GC-content (26) and PAM-proximal high
GC-content (23) have both been found to positively af-
fect sgRNA activity in non-mammalian systems, indicat-
ing species-specific requirements for optimal sgRNA activ-
ity. Of note, the proposed negative impact of PAM mo-
tifs within the sgRNA target region (25), which occur with
increased likelihood in sgRNAs with higher GC-content,
could not be verified in our dataset. This feature was only
marked as a negative one by the sgRNA Designer rule set I
algorithm, which also considers highGC-content as a nega-
tivemarker of sgRNAefficacy (Supplementary Figure S11).
Finally, we performed linear model-based feature analy-
sis of our sgRNA dataset, in order to extend the strength
of our sgRNA efficacy prediction beyond PAM-distal GC.
This resulted in a ten-feature model (CRISPRater). Given
the existing issues with modeling sgRNA efficacy in a con-
tinuous manner, CRISPRater is primarily designed as a dis-
crete selection tool. It is capable of rating sgRNA efficacy
on small sets of sgRNAs -as well as large ones-, and thus
has broad utility for a wide range of projects. Validation of
CRISPRater on small- and large-scale external datasets re-
sulted in an increase in efficacy of up to 1.4-fold, promising
significantly improved signal-to-noise rates in future studies
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based on our work. These findings strongly support trans-
ferability to multiple experimental settings.
Despite these advances towards more uniform, highly ac-
tive genome editing with the CRISPR–Cas9 system, our
work also highlights the limitations of current genome edit-
ing predictions, as seen by the moderate predictivity of
intermediate genome editing activity of all current algo-
rithms. Studies like ours and others before (22,24,27–29)
have mainly been focused on correlating sgRNA nucleotide
composition to genome editing activity at the single nu-
cleotide or small motif level. Larger studies with uniform,
highly quantifiable detection systems will be needed to suc-
cessfully evaluate the effects of larger sequence motifs or
sgRNA secondary structures. Beyond the sgRNA compo-
nent, Cas9 target finding, binding, and nuclease domain ac-
tivation independent of a matching sgRNA may be factors
not yet properly evaluated by current studies (7,8,17,18).
At last, the understanding of factors that potentially affect
genome editing activity at different loci and in different ex-
perimental settings may be challenged by new findings on
sgRNA or Cas9 function, as well as on sgRNA–Cas9 inter-
action, all of which could expand the repertoire of variables
to be included in future in silico predictions.
Apart from the benefits and limitations in silico predic-
tion of genome editing activity provides for diverse applica-
tions, increased monitoring for off-target activities may be
warrantedwith increased on-target activity––whichwe have
partially addressed by implementing CRISPRater into the
off-target evaluation platform CCTop (33). Furthermore,
future studies may incorporate on-target activity predic-
tions like CRISPRater into the evaluation of potential off-
target sites, and thus their risk stratification.
As of yet, high-confidence prediction of genome edit-
ing efficacy remains a challenge. With what is currently an
unique approach involving large-scale assessment of indi-
vidual sgRNA efficacies at the single-cell level, and utilizing
widely-applied delivery tools (31,32,48) inmammalian cells,
we were able to develop and provide CRISPRater––(http://
crispr.cos.uni-heidelberg.de/)––an efficient way to prospec-
tively increase genome editing performancewith concurrent
prediction of potential off-target sites.
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